GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response

被引：36

作者：

Cheramy, Mikael ^{[1
,2
]}

Skoglund, Camilla ^{[1
,2
]}

Johansson, Ingela ^{[1
,2
]}

Ludvigsson, Johnny ^{[1
,2
]}

Hampe, Christiane S. ^{[3
]}

Casas, Rosaura ^{[1
,2
]}

机构：

[1] Linkoping Univ, Div Paediat, Dept Clin & Expt Med, S-58185 Linkoping, Sweden

[2] Linkoping Univ, Dept Clin & Expt Med, Diabet Res Ctr, S-58185 Linkoping, Sweden

[3] Univ Washington, Dept Med, Seattle, WA USA

来源：

CLINICAL IMMUNOLOGY | 2010年 / 137卷 / 01期

基金：

瑞典研究理事会; 英国医学研究理事会;

关键词：

Immunotherapy; GAD(65); GAD-alum; GADA; Type; 1; diabetes; T1D; IgG; IgG subclass; GLUTAMIC-ACID DECARBOXYLASE; STIFF-PERSON-SYNDROME; BETA-CELL FUNCTION; IMMUNE-RESPONSES; C-PEPTIDE; INSULIN; ONSET; ANTIBODIES; MELLITUS; AUTOANTIBODIES;

D O I：

10.1016/j.clim.2010.06.001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We have previously shown that two injections of 20 mu g GAD-alum to recent onset type 1 diabetic children induced GADA levels in parallel to preservation of insulin secretion. Here we investigated if boosted GADA induced changes in IgG1, 2, 3 and 4 subclass distributions or affected GAD(65) enzyme activity. We further studied the specific effect of GAD-alum through analyses of IA-2A, tetanus toxoid and total IgE antibodies. Serum from children receiving GAD alum or placebo was collected pre-treatment and after 3, 9, 15 and 21 months. At 3 months a reduced percentage of IgG1 and increased IgG3/IgG4 were detected in GAD-alum treated. Further, IA-2A, IgE and tetanus toxoid antibodies, as well as GAD(65) enzyme activity, were unaffected confirming the specific effect of treatment. In the GAD-alum group, higher pretreatment GADA were associated to more pronounced C-peptide preservation. The induced IgG3/IgG4 and reduced IgG1 suggest a Th2 deviation of the immune response. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：31 / 40

页数：10

共 35 条

[1] GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes [J].

Agardh, C. -D. ;

Lynch, K. F. ;

Palmer, M. ;

Link, K. ;

Lernmark, A. .

DIABETOLOGIA, 2009, 52 (07) :1363-1368

[2] Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes [J].

Agardh, CD ;

Cilio, CM ;

Lethagen, Å ;

Lynch, K ;

Leslie, RDG ;

Palmér, M ;

Harris, RA ;

Robertson, JA ;

Lernmark, Å .

JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2005, 19 (04) :238-246

[3] Islet cell antibody frequency differs from that of glutamic acid decarboxylase antibodies/IA2 antibodies after diagnosis of diabetes [J].

Borg, H ;

Marcus, C ;

Sjöblad, S ;

Fernlund, P ;

Sundkvist, G .

ACTA PAEDIATRICA, 2000, 89 (01) :46-51

[4] FACTORS ASSOCIATED WITH EARLY REMISSION OF TYPE-I DIABETES IN CHILDREN TREATED WITH CYCLOSPORINE [J].

BOUGNERES, PF ;

CAREL, JC ;

CASTANO, L ;

BOITARD, C ;

GARDIN, JP ;

LANDAIS, P ;

HORS, J ;

MIHATSCH, MJ ;

PAILLARD, M ;

CHAUSSAIN, JL ;

BACH, JF .

NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (11) :663-670

[5] European Nicotinamide Diabetes Intervention Trial (ENDIT):: a randomised controlled trial of intervention before the onset of type 1 diabetes [J].

Gale, EAM ;

Bingley, PJ ;

Knip, M ;

Emmett, CL ;

Swankie, H ;

Fewell, S ;

Kearsey, P ;

Schober, E ;

Gorus, FK ;

Dupre, J ;

Mahon, JL ;

Profozic, V ;

Reimers, JI ;

Mandrup-Poulsen, T ;

Levy-Marchal, C ;

Jaeger, C ;

Bartsocas, C ;

Vazeou, A ;

Györko, M ;

Soltesz, G ;

Madacsy, L ;

Pastore, MR ;

Pozzilli, P ;

Dahl-Jorgensen, K ;

Joner, G ;

Kinalska, I ;

Mrozikiewicz, A ;

Vaykhonsky, Y ;

de Leiva, A ;

Martinez-Larrad, MT ;

Mauricio, D ;

Serrano-Rios, M ;

Ludvigsson, J ;

Schoenle, EJ ;

Yilmaz, MT ;

Carson, DJ ;

Tennet, H ;

Robertson, K ;

Gillespie, KM ;

Gillmor, H ;

Moore, WPT ;

Norcross, A ;

Williams, AJK ;

Dinesen, B ;

Kjellberg, S ;

Akelsen, HE ;

Thorsby, E ;

Undlien, DE ;

Collier, T ;

Hardy, P .

LANCET, 2004, 363 (9413) :925-931

[6] A NOVEL RADIOLIGAND BINDING ASSAY TO DETERMINE DIAGNOSTIC-ACCURACY OF ISOFORM-SPECIFIC GLUTAMIC-ACID DECARBOXYLASE ANTIBODIES IN CHILDHOOD IDDM [J].

GRUBIN, CE ;

DANIELS, T ;

TOIVOLA, B ;

LANDINOLSSON, M ;

HAGOPIAN, WA ;

LI, L ;

KARLSEN, AE ;

BOEL, E ;

MICHELSEN, B ;

LERNMARK, A .

DIABETOLOGIA, 1994, 37 (04) :344-350

[7] Pancreatic β-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes [J].

Harrison, LC ;

Honeyman, MC ;

Steele, CE ;

Stone, NL ;

Sarugeri, E ;

Bonifacio, E ;

Couper, E ;

Couper, JJ ;

Colman, PG .

DIABETES CARE, 2004, 27 (10) :2348-2355

[8] A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes [J].

Herold, KC ;

Gitelman, SE ;

Masharani, U ;

Hagopian, W ;

Bisikirska, B ;

Donaldson, D ;

Rother, K ;

Diamond, B ;

Harlan, DM ;

Bluestone, JA .

DIABETES, 2005, 54 (06) :1763-1769

[9] IgG4-subclass of glutamic acid decarboxylase antibody is more frequent in latent autolmmune diabetes in adults than in type 1 diabetes [J].

Hillman, M ;

Törn, C ;

Thorgeirsson, H ;

Landin-Olsson, M .

DIABETOLOGIA, 2004, 47 (11) :1984-1989

[10] The glutamic acid decarboxylase 65 immunoglobulin G subclass profile differs between adult-onset type 1 diabetes and latent autoimmune diabetes in adults (LADA) up to 3 years after clinical onset [J].

Hillman, M. ;

Torn, C. ;

Landin-Olsson, M. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 157 (02) :255-260

← 1 2 3 4 →